DCTH (Delcath Systems) Quality Rank


DCTH Delcath Systems Inc DCTH
72 GF Score
Price $13.52
GF Value $37.10
Valuation Significantly Undervalued
! 5 Warning Signs
View Full Analysis

What is Delcath Systems Quality Rank?

The Quality Rank measures the business quality of a company relative to other companies. It is ranked based on the strength of the balance sheet, as well as the profitability and growth of the business. The ranked companies are split in equal numbers and then ranked from 1 to 10, with 10 being the highest.

The rank of balance sheet (30%)

The rank of balance sheet is done through the ranking of:
  • Interest coverage
  • Zscore
  • Debt to revenue
  • Equity to asset
  • Cash to debt

The rank of Profitability (70%)

The ranking of Profitability is done by ranking:
  • Operating margin mean rank (10-year mean average profit margine)
  • Operating margin growth rank
  • Fscore
  • Predictability rank
  • Revenue growth rank (5 year), when the growth is higher than 25%, set it as 25%
  • Num of year profit (number of years that is profitable within the last 10 years)
  • ROIC median (10-year median of ROIC)

Delcath Systems Quality Rank Related Terms

DCTH
72GF Score
Delcath Systems Inc DCTH
Quality Rank is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Is Delcath Systems (DCTH) Overvalued in 2026?

Based on GuruFocus' analysis, Delcath Systems stock appears to be undervalued. The current stock price of $13.52 is trading 63.6% below its estimated GF Value™ of $37.10. GuruFocus considers Delcath Systems to be Significantly Undervalued.

Key valuation signals for DCTH:

  • Quality Rank:
  • GF Value™: $37.10 vs. price of $13.52 (63.6% below fair value)
  • GF Score™: 72/100 with 5 warning signs

No single metric tells the full story. See the DCTH stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.

Delcath Systems Business Description

Other Exchanges DV3R:Germany
Address 566 Queensbury Avenue, Queensbury, NY, USA, 12804
Delcath Systems Inc is an oncology company. The company is focused on the treatment of primary and metastatic liver cancers. The firm's product include Melphalan Hydrochloride, Hepzato for Injection along with the Delcath Hepatic Delivery System, or Melphalan/HDS, is a drug and device combination product, designed to administer high-dose chemotherapy to the liver while controlling systemic exposure and associated side effects. The company operates in one reportable segment which includes the research, development, manufacture, and distribution of hepatic delivery systems for use in the treatment of specific conditions. The Company operates its business in the United States and Europe.
72GF Score

Get the complete analysis for DCTH

Quality Rank is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

$13.52
Price
$37.10
GF Value